Senseonics and newcomer pump developer Sequel Med Tech have a plan to connect their diabetes technologies, with the goal of ...

An approval decision for Stealth BioTherapeutics’ investigational treatment for an ultra-rare genetic disease has been ...

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed ...

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

Octagon Therapeutics has thrown in the towel. The Novo Nordisk-allied autoimmune disease biotech is winding down after ...

Oberland Capital Management is pumping some new life into Biohaven, striking a unique investment deal worth up to $600 ...

Three Senate Democrats called for an investigation into the developers of brain-computer interface devices, including ...

Ferrer’s R&D work focuses on neurological and pulmonary diseases, and the Spanish pharma has bought into ALS assets in the ...

In February, the HHS unexpectedly delivered notice that the South San Francisco-based company was to stop all work on the ...

Novartis has done a little spring cleaning, sweeping a phase 2 osteoarthritis prospect and first-in-human radioconjugate out of its pipeline after assessing evidence on the programs. | Novartis has ...

The former head of Johnson & Johnson’s worldwide medtech business, Ashley McEvoy, has signed up to lead the insulin ...

The CEO of Novo Holdings has warned that his $160 billion fund will slow down investment activity until the dust settles ...